Corvus Pharmaceuticals, Inc. (CRVS) Misses Q4 EPS by 2c

Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) reported Q4 EPS of ($0.14), $0.02 worse than the analyst estimate of ($0.12).

For earnings history and earnings-related data on Corvus Pharmaceuticals, Inc. (CRVS) click here.

You May Also Be Interested In

• Westinghouse said to seek over $50 billion valuation in planned IPO
• Investing.com’s stocks of the week
• Wells Fargo cuts Netflix rating on engagement risk, weak slate